Short answer
PTC THERAPEUTICS, INC. (PTCT) filed an 8-K current report with the SEC on August 28, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). PTC to acquire ST-920, one-time AAV gene therapy candidate for Fabry disease, expanding its rare-disease pipeline.
PTC THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- PTC to acquire ST-920, one-time AAV gene therapy candidate for Fabry disease, expanding its rare-disease pipeline
- Upfront consideration of $111 million plus up to $100 million in FDA approval milestones
- Milestones: $80 million for accelerated approval and $20 million for full approval
- Closing requires Delaware Bankruptcy Court approval, antitrust clearance, and other customary conditions
- Approval hearing scheduled September 10, 2026; either party may terminate if closing misses October 15, 2026, subject to exceptions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PTC THERAPEUTICS, INC. 8-K filings
Get the next PTCT 8-K as it lands
Follow PTCT for push alerts, or ask the research agent what this filing means.